



THE WHITE HOUSE
WASHINGTON

COVID-19 Press Briefing

March 17, 2021



Daily Change in COVID-19 Cases, US

January 22, 2020 – March 15, 2021



TOTAL Cases Reported Since 1/22/20

29,237,551

NEW Cases Reported to CDC on 3/15/21

45,860

Change in 7-Day Case Average

-5.2%


Current 7-Day Case Average (3/9/21 - 3/15/21)

53,014

Prior 7-Day Case Average (3/2/21 - 3/8/21)

55,904

Peaks in New Cases and Highest 7-Day Moving Average		
	Highest Daily Number of New Cases	Highest 7-Day Moving Average
Current	314,180 (1/8/21)	249,378 (1/11/21)
2nd Peak	75,192 (7/17/20)	67,277 (7/23/20)
1st Peak	42,597 (4/6/20)	31,933 (4/12/20)



● Latest ● New Cases ● Peak — 7-Day Moving Average - New Cases*

*7-day averages exclude historical cases reported retroactively by states



New Admissions of Patients with Confirmed COVID-19

August 1, 2020 – March 14, 2021

Patients Currently Hospitalized with COVID on 3/14/21

32,515

New Admissions on 3/14/21

3,984

Peak in New Admissions (1/5/21)

18,009

Change in 7-Day Average of New Admissions


-5.7%

Current 7-Day Average of New Admissions (3/8/21 - 3/14/21)

4,713

Prior 7-Day Average of New Admissions (3/1/21 - 3/7/21)

4,997



Daily Change in COVID-19 Deaths, United States

January 22, 2020 – March 15, 2021

TOTAL Deaths Reported Since 1/22/2020

533,057

NEW Deaths Reported to CDC on 3/15/21

702

Change in 7-Day Death Average

-30.0%

Current 7-Day Death Average (3/9/21 - 3/15/21)


1,145

Prior 7-Day Death Average (3/2/21 - 3/8/21)

1,635


Forecasted Total Deaths by 4/3/21

547,000 - 571,000





WEAR A MASK




STAY 6 FEET APART








AVOID CROWDS



AVOID TRAVEL



Selected COVID-19 Vaccines

Platform		Developer	Status
Nucleic Acid (mRNA)		moderna	■ EUA
		BIONTECH Pfizer	■ EUA
Adenovirus Vector		Johnson & Johnson	■ EUA
		AstraZeneca 	■ EUA TBD
Recombinant Protein and Adjuvant		gsk SANOFI 	■ Phase 2 clinical trial launched Feb. 2021
		NOVAVAX Creating Tomorrow's Vaccines Today	■ EUA TBD

Efficacy

Versus

Effectiveness





The
New England
Journal of Medicine

Established in 1812 as THE NEW ENGLAND JOURNAL OF MEDICINE AND SURGERY

Published online February 24, 2021

BNT162b2 mRNA COVID-19 Vaccine in a Nationwide Mass Vaccination Setting

LN Dagan, RD Balicer et al.

- 600,000 newly vaccinated people and 600,000 matched controls in Israel

Vaccine effectiveness	Days 14-20 after 1st dose	7 or more days after 2nd dose
Documented infection	46%	92%
Symptomatic COVID-19	57%	94%
Severe disease	62%	92%



Preprints with **THE LANCET**

Published online February 22, 2021

Effectiveness of BNT162b2 mRNA Vaccine Against Infection and COVID-19 Vaccine Coverage in Healthcare Workers in England, Multicentre Prospective Cohort Study (the SIREN Study)

VJ Hall, S Hopkins et al.

- **British healthcare workers vaccinated with BNT162b2 and undergoing regular asymptomatic testing**
- **Vaccine effectiveness against both asymptomatic and symptomatic infection (B.1.1.7 variant predominated during study period)**
 - **at least 70% 21 days after the first dose**
 - **at least 85% 7 days after the second dose**



Published online
March 10, 2021



Clinical Infectious Diseases

Impact of the COVID-19 Vaccine on Asymptomatic Infection Among Patients Undergoing Pre-Procedural COVID-19 Molecular Screening

AJ Tande, EF Berbari et al.

- Retrospective study of >39,000 asymptomatic adults who underwent pre-procedural SARS-CoV-2 screening tests
- After adjustment for confounding factors, 80% reduction in the risk of a positive screening test in persons who received 2 doses of an mRNA vaccine (>0 days after 2nd dose)



Transmission of COVID-19 in 282 Clusters in Catalonia, Spain: A Cohort Study

M Marks, O Mitjà et al.

- **Viral load is proxy for infectiousness**

February 8, 2021

medRxiv

THE PREPRINT SERVER FOR HEALTH SCIENCES

Decreased SARS-CoV-2 Viral Load Following Vaccination

M Levine-Tiefenbrun, R Kishony et al.

- **In “breakthrough” infections viral load reduced 4-fold for infections occurring 12-28 days after the first dose of vaccine**



THE WHITE HOUSE
WASHINGTON

WH.GOV